The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Subscribe To Our Newsletter & Stay Updated
